Le Lézard
Classified in: Health
Subjects: RCL, CFG

Advisory - Herberex may pose serious health risks; Health Canada suspends product licence


OTTAWA, ON, Dec. 31, 2021 /CNW/ -

Summary

Issue
Health Canada is warning consumers not to use Herberex, advertised as an herbal product for sexual enhancement, because it may pose serious health risks. Herberex was authorized as a natural health product, but Health Canada testing found the product contains nortadalafil.

Nortadalafil is an unauthorized ingredient that is similar to tadalafil, which is a prescription erectile dysfunction drug that should only be used under the supervision of a health care professional. Nortadalafil may pose similar health risks as tadalafil. Individuals taking any kind of nitrate drug (e.g., nitroglycerine) should not take drugs like tadalafil as the interaction can cause potentially life-threatening low blood pressure. Individuals with heart problems are at increased risk of cardiovascular side effects such as heart attack, stroke, chest pain, high blood pressure and abnormal heartbeat. Other possible side effects include headache, facial flushing, indigestion, dizziness, abnormal vision, and hearing loss.  

Health Canada has suspended the product licence for Herberex (NPN 80029339) given the health risks posed by the product. It is illegal for any person or company to sell this product in Canada.

Health Canada previously seized Herberex from three stores:

The Department is working with the Canada Border Services Agency to help prevent further importation of Herberex. If any new health risks are identified, Health Canada will take action and inform Canadians as needed.

Affected products

Product

Company

NPN

Herberex

Nutraloid Labs Inc.

80029339 (suspended)

What you should do

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:25
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...



News published on and distributed by: